Technology
Health
Biotechnology

Xencor

$32.32
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.

+$2.05 (6.77%) Today
$0.00 (0.00%) After Hours

Why Robinhood?

You can buy or sell Xencor and other stocks, options, ETFs, and crypto commission-free!

About

Xencor, Inc. engages in the development of engineered monoclonal antibody therapeutics to treat severe and life-threatening diseases. Its proprietary technology platform, XmAb, is used to create next-generation antibody product candidates designed to treat autoimmune and allergic diseases, cancer, and other conditions. Read More The company was founded by Bassil I. Dahiyat and Stephen L. Mayo in August 1997 and is headquartered in Monrovia, CA.

Employees
156
Headquarters
Monrovia, California
Founded
1997
Market Cap
1.70B
Price-Earnings Ratio
Dividend Yield
0.00
Average Volume
276.38K
High Today
$35.29
Low Today
$30.00
Open Price
$30.44
Volume
1.02M
52 Week High
$48.38
52 Week Low
$27.57

Collections

Technology
Health
Biotechnology
Therapy
Cancer Prevention
2013 IPO
US
North America

News

MarketBeatMar 9

Stock Price, News, & Analysis for Xencor

Xencor, Inc., a clinical stage biopharmaceutical company, focuses on the discovery and development of engineered monoclonal antibody therapeutics to treat severe and life threatening diseases with unmet medical needs. It develops its antibody product candidates to treat autoimmune and allergic diseases, cancer, and other conditions. The company's product candidates include XmAb5871, an immune inhibitor, which is in Phase II clinical trial for the treatment of autoimmune diseases; and XmAb7195, an immune inh...

28
Markets InsiderMar 8

Xencor Announces Closing of Research Collaboration and License Agreement with Genentech

Xencor, Inc. (NASDAQ:XNCR), a clinical-stage biopharmaceutical company developing engineered monoclonal antibodies for the treatment of autoimmune disease, asthma and allergic diseases, and cancer, today announced the closing of its research collaboration and license agreement with Genentech, a member of the Roche Group, following the expiration of the waiting period under the Hart-Scott Rodino Antitrust Improvements Act of 1976. Xencor and Genentech entered the agreement to develop and commercialize novel ...

93
The Motley FoolMar 3

3 Top Biotech Stocks to Buy Right Now

It's hard to beat the world of biotech investing when it comes to sheer excitement. Biotechs announce major news almost on a daily basis, whether it's clinical updates, deals, or financial reports. But while some investors might like the excitement, every investor likes a shot at making a solid return. We asked three Motley Fool contributors to pick the biotech stocks that they think provide great prospects of generating those solid returns that investors crave. Here's why they chose Celgene (NASDAQ:CELG),...

1,170

Earnings

-$0.62
-$0.40
-$0.17
$0.05
Q2 2017
Q3 2017
Q4 2017
Q1 2018
Q2 2018
Q3 2018
Q4 2018
Q1 2019
Estimated
Actual
Expected May 6, After Hours
All investments involve risk and the past performance of a security, or financial product does not guarantee future results or returns. Securities offered through Robinhood Financial LLC, member FINRA/SIPC. To learn more about the information provided on this page, please see our Web Disclosures.